Skip to content

Intercept Pharmaceuticals, Inc.

CIK 0001270073

← back to feed
Revenue (TTM)
$318.05M
−0.5% YoY Q3 Nov 2023
Net Income (TTM)
$226.67M
−107.8% YoY Q3 Nov 2023
EPS Diluted (TTM)
$6.82
−106.4% YoY Q3 Nov 2023
Gross Margin
99.7%
Q3 Nov 2023
Operating Margin
-16.8%
Q3 Nov 2023
Net Margin
71.3%
Q3 Nov 2023
Free Cash Flow (TTM)
−$226.65M
Q3 Nov 2023
Cash
$102.74M
Q3 Nov 2023
Total Debt
$333.66M
Q3 Nov 2023
Shares Outstanding
41.83M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings